A phase II study of docetaxel for the treatment of recurrent osteosarcoma

Sarcoma

Volumn 8, Issue 2-3, 2004, Pages 71-76

  McTiernan, Anne ^a   Whelan, Jeremy S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Bone tumours; Osteosarcoma; Taxanes; Taxotere

Indexed keywords

CISPLATIN; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL DISEASE; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFECTION; INFUSION; LETHARGY; LEUKOCYTE COUNT; LUNG METASTASIS; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEPSIS; SPINDLE CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 10844236347     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140410001711764     Document Type: Article

References (33)

1. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911-7.
2. Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 488-94.
3. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16: 2452-8.
4. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-9.
5. Bacci G, Briccoli A, Mercuri M, Ferrari S, Bertoni F, Gasbarrini A, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998; 10: 69-76.
6. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-90.
7. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-5.
8. Bielack SS, Kempf-Bielack B, Branscheid D, Helmke K, Kabisch H, Kotz R, et al. Relapsed osteosarcoma: An analysis of 576 Cooperative Osteosarcoma Study Group (COSS) patients. Proc Am Soc Clin Oncol 2003; 22: 3305.
9. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995; 75: 1084-93.
10. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91.
11. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
12. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016-9.
13. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
14. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341-54.
15. Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nistico C, et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol 2000; 23: 132-9.
16. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70: 380-3.
17. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8.
18. Meyer T, McTiernan A, Whelan J. A phase II study of docetaxel in patients with relapsed and refractory Ewing's tumours. Sarcoma 2003; 7: 13-7.
19. Edmonson JH, Ebben LP, Nascimento AG, Jung SH, McGaw H, Gerstner JB. Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 1996; 19: 574-6.
20. van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5: 539-42.
21. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18: 2081-6.
22. Peng L, Wang Z, Wang Q. Docitaxol-induction apoptosis of osteosarcoma. Zhonghua Zhong Liu Za Zhi 2001; 23: 190-2.
23. Burns BS, Edin ML, Lester GE, Tuttle HG, Wall ME, Wani MC, et al. Selective drug resistant human osteosarcoma cell lines. Clin Orthop 2001: 259-67.
24. Pronk LC, Schellens JH, Planting AS, van den Bent MJ, Hilkens PH, van der Burg ME, et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071-9.
25. Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 750-8.
26. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-24.
27. World Health Organisation. Handbook for reporting results of cancer treatment. World Health Organisation Offset Publication No. 48. Geneva: World Health Organisation, 1979.
28. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS March, 1998:
29. Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 1997; 15: 1538-43.
30. Seibel NL, Blaney SM, O'Brien M, Krailo M, Hutchinson R, Mosher RB, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 1999; 5: 733-7.
31. Patel SR, Papadopoulos NE, Plager C, Linke KA, Moseley SH, Spirindonidis CH, et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 1996; 78: 741-4.
32. Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, et al. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer 2001; 84: 604-10.
33. Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 2003; 25: 539-42.